PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation
Cancer Medicine · 2025-07 · 14 (13)
DOI: 10.1002/cam4.71005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.06.2025. Verfasst von Mei Dai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Mitochondria, Oxidative Phosphorylation, Peroxiredoxin VI. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Peroxiredoxin 6 (PRDX6) scavenges reactive oxygen species (ROS) and plays a key role in antioxidant defense. Although PRDX6 is involved in various cancers, its role in breast cancer (BRCA) remains unclear.
Methods
Cell proliferation was assessed using CCK‐8, EdU staining, and colony formation assays. Migration and invasion were evaluated via wound‐healing and transwell assays. ROS levels and mitochondrial membrane potential were measured by fluorescence microscopy or flow cytometry. Oxidative phosphorylation (OXPHOS) activity was determined by ATP production and NAD + /NADH ratio. Mitochondria were visualized by TEM, and mitochondrial complex subunits were detected by quantitative real‐time PCR and Western blotting. In vivo effects were evaluated using a xenograft tumor model.
Results
Although PRDX6 was downregulated in BRCA overall, it showed elevated expression in aggressive subtypes and advanced‐stage tumors, correlating with poor prognosis. Overexpression of PRDX6 enhanced BRCA cell proliferation, migration, and invasion. PRDX6 reduced ROS levels, upregulated mitochondrial transcription factor A (TFAM) expression, and promoted mitochondrial complex subunit expression and OXPHOS. Inhibition of TFAM led to a decrease in the expression of some of the mitochondrial complex subunits, which reversed the pro‐carcinogenic phenotype of the tumor. PRDX6 also promoted tumor growth in vivo.
Conclusion
PRDX6 maintains intracellular homeostasis by reducing ROS and promotes mitochondrial biogenesis and OXPHOS through TFAM‐dependent and ‐independent pathways, driving BRCA progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Clinical Research Center for Breast Disease of Hunan Province, Changsha, Hunan, China.
ORCID-Profile: Danhua Zhang
Zitieren
APA
Dai, M., & Zhang, D. (2025). PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation. Cancer Medicine, 14(13). https://doi.org/10.1002/cam4.71005
Vancouver
Dai M, Zhang D. PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation. Cancer Medicine. 2025;14(13). doi:10.1002/cam4.71005
BibTeX
@article{Dai2025,
author = {Dai, Mei and Zhang, Danhua},
title = {PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {13},
doi = {10.1002/cam4.71005}
}
EUVIMED